Literature DB >> 27475095

Diagnostic accuracy of two tests for determination of anti-m2 in the diagnosis of primary biliary cirrhosis: Is it possible to predict the course of the disease?

Antonio Maria Alfano1, Alessandra Romito2, Cristiana Marchese3, Marco Battistini4, Giliola Crotti4, Arturo Ferrini4, Cristina Mancinetti4, Tilde Manetta5, Giulio Mengozzi5, Paola Merlach4, Marco Migliardi3, Maria Teresa Tambuzzo4.   

Abstract

To evaluate the analytical agreement between results obtained from the indirect immunofluorescence methods and from the multiplexed line-blot assay and EliA-M2, to analyze the diagnostic accuracy in a cohort of primary biliary cirrhosis (PBC) patients and in control patients of two different types of tests for anti-M2 and assess whether, with the advent of a quantitative test, the possibility exists to correlate disease activity with the value of AMA. Serum analysis of 67 patients with fluorescence patterns detected on Hep-2 cells suggestive of PBC-related antibodies and three groups of patients (15 PBC, 16 PBC suspect and 48 disease controls) was carried out. All samples were tested by both a qualitative test multiplexed line-blot Autoimmune Liver Disease Profile Euroline and by a quantitative test EliA-M2 IgG. In order to evaluate a possible correlation between the quantitative M2 and disease activity, we divided patients mixed in a further three groups based on the value EliA-M2. For each of these groups were calculated the average values of the main indices of cholestasis. A perfect agreement was shown between the EliA-M2 and the multiplexed line-blot method for AMA detection. All sera of patients with PBC were positive with both tests, with a 100 % sensitivity. Forty-seven of the 48 sera of the control group were negative for both tests with a 100 % next specificity, and only 70 % for the AMA-IIF. We had also observed in the other three groups of patients that the average of the values of γ-glutamyl transpeptidase and alkaline phosphatase increases with the increase of the value EliA-M2. The difference between the mean values of the most significant parameter which the alkaline phosphatase of the three groups is significant, with a statistically significant difference between the first and the third group (p value 0.023). Both the qualitative method Profile Euroline and the quantitative EliA-M2 have a high diagnostic accuracy for PBC, with a specificity higher than the immunofluorescence method. These preliminary data might suggest the possibility of using the dosage EliA-M2 not only in the diagnosis phase but also in the monitoring of disease activity.

Entities:  

Keywords:  Anti-mitochondrial antibodies; Antinuclear PBC-correlated antibodies; Indirect immunofluorescence microscopy; Primary biliary cirrhosis; Prognosis; Solid phase methods

Mesh:

Substances:

Year:  2017        PMID: 27475095     DOI: 10.1007/s12026-016-8838-2

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  37 in total

Review 1.  Primary biliary cirrhosis.

Authors:  Marshall M Kaplan; M Eric Gershwin
Journal:  N Engl J Med       Date:  2005-09-22       Impact factor: 91.245

2.  EASL Clinical Practice Guidelines: management of cholestatic liver diseases.

Authors: 
Journal:  J Hepatol       Date:  2009-06-06       Impact factor: 25.083

3.  Primary biliary cirrhosis.

Authors:  Keith D Lindor; M Eric Gershwin; Raoul Poupon; Marshall Kaplan; Nora V Bergasa; E Jenny Heathcote
Journal:  Hepatology       Date:  2009-07       Impact factor: 17.425

4.  Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrhosis.

Authors:  J Van de Water; A Cooper; C D Surh; R Coppel; D Danner; A Ansari; R Dickson; M E Gershwin
Journal:  N Engl J Med       Date:  1989-05-25       Impact factor: 91.245

5.  The Western immunoblotting pattern of anti-mitochondrial antibodies is independent of the clinical expression of primary biliary cirrhosis.

Authors:  L Muratori; P Muratori; A Granito; R Ferrari; L Veronesi; M Lenzi; F B Bianchi
Journal:  Dig Liver Dis       Date:  2005-02       Impact factor: 4.088

6.  Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients.

Authors:  Christophe Corpechot; Fabrice Carrat; Raoul Poupon; Renee-Eugenie Poupon
Journal:  Gastroenterology       Date:  2002-03       Impact factor: 22.682

7.  Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis?

Authors:  H C Mitchison; M F Bassendine; A Hendrick; M K Bennett; G Bird; A J Watson; O F James
Journal:  Hepatology       Date:  1986 Nov-Dec       Impact factor: 17.425

8.  Autoantibody profiling of patients with primary biliary cirrhosis using a multiplexed line-blot assay.

Authors:  Danilo Villalta; Maria Concetta Sorrentino; Elia Girolami; Marilina Tampoia; Maria Grazia Alessio; Ignazio Brusca; Massimo Daves; Brunetta Porcelli; Giuseppina Barberio; Nicola Bizzaro
Journal:  Clin Chim Acta       Date:  2014-08-27       Impact factor: 3.786

9.  Primary biliary cirrhosis: prediction of short-term survival based on repeated patient visits.

Authors:  P A Murtaugh; E R Dickson; G M Van Dam; M Malinchoc; P M Grambsch; A L Langworthy; C H Gips
Journal:  Hepatology       Date:  1994-07       Impact factor: 17.425

Review 10.  Primary biliary cirrhosis.

Authors:  Elizabeth J Carey; Ahmad H Ali; Keith D Lindor
Journal:  Lancet       Date:  2015-09-11       Impact factor: 79.321

View more
  3 in total

1.  Biomarkers and Pathogenic Mechanisms in Autoimmunity.

Authors:  Edward K L Chan; Elias Toubi; Karsten Conrad
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

2.  Clinical significance of IgG antimitochondrial M2 antibody levels in primary biliary cholangitis: A single center study from China.

Authors:  Lina Feng; Kaihui Dong; Xiaoxue Zhang; Bo Ma; Lin Chen; Qianqian Yang; Qingling Chen; Xiaoyu Wen; Qinglong Jin
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.240

3.  Optimization of Laboratory Diagnostics of Primary Biliary Cholangitis: When Solid-Phase Assays and Immunofluorescence Combine.

Authors:  Federica Gaiani; Roberta Minerba; Alessandra Picanza; Annalisa Russo; Alessandra Melegari; Elena De Santis; Tommaso Trenti; Lucia Belloni; Silvia Peveri; Rosalia Aloe; Carlo Ferrari; Luigi Laghi; Gian Luigi de'Angelis; Chiara Bonaguri
Journal:  J Clin Med       Date:  2022-09-05       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.